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ABSTRACT
The purpose of this study was to investigate the 
relationship between fibrinolytic capacity and metabolic 
control in insulin-dependent diabetes mellitus. Testing 
protocol was explained and informed consent was obtained 
from 26 insulin-dependent diabetics and 20 healthy 
controls who agreed to serve as subjects. Fibrinolytic 
capacity (FC) was measured as the change in euglobulin 
lysis time produced by 10 min of venous occlusion with a 
sphygmomanometer cuff inflated around the upper arm at a 
pressure midway between systolic and diastolic blood 
pressure. Metabolic control was evaluated by measurement 
of hemoglobin A1 (HbAl) using a minicolumn chroma­
tographic technique. Fasting glucose (GLU), cholesterol 
(CHO), and triglyceride (TRI) were measured on a Coulter 
Chemistry Analyzer. Significant differences were found 
to exist between diabetics and controls, respectively, 
for FC (46.6 ± 19.3% vs. 64.2 ± 12.1%), HbAl (10.3 ± 2.1% 
vs. 6.5 ± .9%), GLU (209 ± 102 mg% vs. 95 ± 7 mg%) , and 
CHO (215 ± 56 mg% vs. 186 ± 25 mg%). No differences were 
found for TRI. Bivariate correlations were calculated 
between FC and HbAl for diabetics only, for controls 
only, and for all subjects combined. Significant rela­
tionships were found for both the combined sample (r = 
-.33) and for controls (r = .54), but not for diabetics 
(r « -.08). Stepwise linear regression revealed that FC
viii
could best be explained in insulin-dependent diabetes by 
TRI (£ *= .03), and no significance could be attached to 
HbAl (£ *= .46). It is concluded that the positive
relationship noted between FC and HbAl for normal sub­
jects is spurious and that the reduced capacity for 
fibrinolytic activity in insulin-dependent diabetes is 
not directly related to metabolic control.
ix
CHAPTER I 
INTRODUCTION
It has been hypothesized that low fibrinolytic 
activity could lead to vascular disturbances if the end 
products of coagulation are allowed to accumulate on 
vessel surfaces (Astrup, 1956). This premise has been 
the basis of many investigations which have demonstrated 
impaired fibrinolysis in a variety of thromboembolic 
disorders. Insufficient fibrinolytic activity may be 
involved in the pathogenesis of diabetic vascular disease, 
but this point has not been conclusively established.
While numerous investigations concerning fibrin­
olysis in diabetes appear in the literature, they are 
plagued by problems of methodology. Most researchers 
have chosen to study spontaneous fibrinolytic activity, 
but this method is far too insensitive to produce 
definitive results. More consistent results have been 
obtained by examining fibrinolytic capacity, but re­
sponses appear to vary within groups of diabetic sub­
jects.
Recent evidence indicates that diabetes mellitus is 
a heterogeneous disorder which contains many different 
pathophysiological conditions. A new classification 
scheme has been developed which clearly separates 
diabetics who have an absolute deficiency of insulin from
1
those whose deficiency is only relative (National 
Diabetes Data Group, 1979). The latter division contains 
a large number of obese individuals, and excess body fat 
has been shown to be associated with impaired 
fibrinolytic activity (Aimer & Janzon, 1975). The factor 
of obesity can be eliminated fairly well by studying 
diabetics who have an absolute insulin deficiency.
Laboratory techniques have been developed for the 
quantitative determination of diabetic control, and have 
been applied to investigate the role of glucose 
homeostasis in the etiology of diabetic vascular disease 
(Bunn, 1981? Gabbay, Hasty, Breslow, Ellison, Bunn, & 
Gallop, 1977). Available evidence indicates that poor 
metabolic control is associated with a state of 
hypercoagulation (Coller, Frank, Milton, & Gralnick, 
1978; Sowers, Tuck, & Sowers, 1980). An important 
question would, therefore, appear to be: What is the
relationship between control of blood glucose and 
fibrinolytic activity in diabetes mellitus?
Statement of the Purpose
The primary purpose of this investigation was to 
examine the relationship between fibrinolytic capacity 
and metabolic control in insulin-dependent diabetes 
mellitus. Secondarily, a number of moderator variables 
were included to determine their effect on this rela­
tionship.
Research Hypothesis
The following research hypothesis was made for this 
study: Fibrinolytic capacity and metabolic control will
be inversely related; that is, those patients with 
poorest metabolic control will demonstrate lowest 
fibrinolytic capacity.
Operational Definitions
Fibrinolytic capacity: The ability to increase
levels of plasminogen activator above preocclusion values 
(as judged by a decrease in euglobulin lysis time), in 
response to 10 min of venous occlusion.
Metabolic control: The percentage of total hemo­
globin that is comprised of hemoglobin Al.
Assumptions
The following assumptions were made in this study:
1. All subjects adhered to pretest rules regarding 
cigarette smoking, vigorous exercise, and ingestion of 
foods. The pretest Clinical Data Form (Appendix A) 
accurately documents subject cooperation.
2. Clinical records give an accurate description of 
the subjects' dependence on exogenous insulin to sustain 
life.
Limitations
The study is limited as follows:
1. Subjects were volunteers selected from diabetic 
cases seen at Earl K. Long Memorial Hospital. The sample
is not random.
2. Subjects were type I diabetics and this delimi­
tation restricts application of these results only to 
other insulin-dependent diabetic individuals.
3. The small sample size employed in this inves­
tigation limits the power of the statistical analyses.
Significance
Disorders of large and small blood vessels are 
associated with increased morbidity and mortality in 
diabetes mellitus, and have been linked to disturbances 
of the coagulation-fibrinolysis equilibrium. While there 
is good evidence of a hypercoagulable state in diabetes, 
no consensus has been reached concerning fibrinolytic 
activity. Studies have been plagued by inappropriate 
experimental procedures and failure to consider 
pathophysiological differences and coexisting conditions 
which may affect diabetic fibrinolysis.
The capacity for plasminogen activator release in 
response to a standard stimulus, which is held to be a 
valid and reliable method of assessing fibrinolytic 
capacity (Hedner & Nilsson, 1981), was examined. The 
moderating factor of obesity was controlled by the use of 
only type I diabetics. This study should provide useful 
information concerning the relationship between 
fibrinolytic capacity and metabolic control, and should 
have application to guidelines for therapeutic management 
of insulin-dependent diabetes mellitus.
CHAPTER II 
REVIEW OF LITERATURE 
This review deals with various aspects of 
fibrinolysis and diabetes mellitus. The section on 
fibrinolysis includes mechanisms and components of the 
fibrinolytic enzyme system, available techniques for the 
assessment of fibrinolytic activity, and a brief review 
of those studies which have examined both physiological 
and impaired fibrinolysis. The section on diabetes 
mellitus encompasses the heterogeneous nature of the 
disease, methods of measuring metabolic control, and 
studies of hypercoagulation and fibrinolysis in diabetes.
Fibrinolysis
Human blood contains at least one enzymatic system 
capable of removing fibrin deposits from the vascular 
bed. Mechanisms for the enzymatic degradation of fibrin 
remain the subject of controversy, but it is generally 
accepted that the plasminogen-plasmin system is the 
dominant pathway for physiological fibrinolysis 
(Brozovic, 1977; Collen, 1980; Hedner & Nilsson, 1981). 
The plasminogen-plasmin system has been well defined and 
a number of laboratory techniques are available for the 
quantitative study of the activity and components of this 
system. Providing that assumptions regarding the 
importance of plasmin-mediated fibrinolysis are valid, 
these measures can be used to estimate levels of
fibrinolytic activity.
It has been suggested that an equilibrium normally 
exists between coagulation and fibrinolysis which 
provides defense against vascular injury, with the 
subsequent removal of fibrin which has served its 
purpose. A shift in this hemostatic balance toward 
excess fibrin deposition could be an etiological factor 
in thrdmboembolic disease (Astrup, 1956). Research in 
the past three decades has firmly established the 
fibrinolytic system as an essential factor in normal 
hemostasis (Kernoff & McNicol, 1977; McNicol & Douglas, 
1976). Investigators have studied components of the 
fibrinolytic system in numerous vascular disorders and 
have established significant relationships between 
impaired fibrinolysis and occlusive vascular disease. 
Mechanians and Oonponents of the Fibrinolytic Enzyme System
The classical theory of fibrinolysis involves the 
basic mechanisms and components introduced by Christensen 
and Macleod in 1945. This system consists of a number of 
elements that either promote or inhibit the conversion of 
a circulating proenzyme, plasminogen, to the active 
protease, plasmin, which in turn digests fibrin. A 
simplified scheme of the plasminogen-plasmin system is 
presented in the Figure.
Plasminogen is present in human plasma in a concen­
tration of 10-15 mg/100 ml (Heimburger, 1971). Plasmin-
PLASMINOGEN
ACTIVATORS
Antiactivators (?)
----------►  PLASMIN
^  Antiplasmins
FIBRIN----------►  FIBRIN DEGRADATION
PRODUCTS
Figure. Schematic representation of the plasminogen- 
plasmin system
ogen levels may be assayed immunologically (Ganrot & 
Nilehn, 1968), or functionally by lysis of fibrin (Berg, 
Korsan-Bengston, & Ygge, 1966). Although low levels of 
plasminogen could potentially be considered a mechanism 
for reduced fibrinolytic activity, there is relatively 
little documentation of patients with hypofibrinolysis 
due to this abnormality. Acute thrombolytic therapy may 
be associated with drastically reduced plasminogen 
levels, but synthesis is rapid and levels have been shown 
to return to normal from zero within 24 hours of stopping 
therapy (Davidson & Walker, 1979). Levels of plasminogen 
may also be reduced in hepatic cirrhosis, but fibrino­
lytic activity is not similarly reduced because of 
increased availability of activators of plasminogen 
(Fletcher, Biederman, & Moore, 1964). Deficiencies of 
plasminogen seem to be rare and are not particularly 
associated with thromboembolism.
Providing that plasminogen is available in normal 
concentrations, the critical step in the plasminogen- 
plasmin system is at the level of plasminogen activation. 
Activation may occur by three different pathways: an
intrinsic or humoral pathway in which all components are 
found in circulating blood, an extrinsic pathway in which 
activators are released into the blood from tissues or 
from the vessel wall, or an exogenous pathway in which
chemical substances are administered for therapeutic 
purposes.
The intrinsic pathway involves indirect formation of 
plasminogen activators (PA) by systems consisting of 
factor XII (Hageman factor), high molecular weight 
kininogen (Fitzgerald factor), prekallikrein (Fletcher 
factor), and possibly other components (Revak & Cochrane, 
1976). Activation of the fibrinolytic system by this 
pathway requires the presence of a surface (Ogston & 
Bennett, 1978). The importance of intrinsic activation 
in physiological fibrinolysis has not been firmly 
established and the mechanisms involved are not without 
controversy (Ratnoff, 1977).
Plasminogen activators are known to be widely 
distributed throughout the body (Astrup, 1966). These 
activators are usually named according to the source from 
which they are isolated: tissue activator from tissue
(lung, heart, spleen, intestine, uterus) homogenates, 
vascular activator released from vessel walls, and 
urokinase which is present in urine (Rijken, Wijngaards, 
& Welbergen, 1980, 1981). A small amount of PA can be 
detected in human blood drawn in the resting state 
without venous occlusion, and despite avoidance of 
surfaces that activate factor XII (Fearnley, 1964). The 
level of PA found at rest is thought to be released by 
the vascular endothelium and is responsible for sponta­
neous fibrinolytic activity (Nilsson & Pandolfi, 1970; 
Todd, 1959). This concept is supported by demonstrations 
of synthesis and release of PA by endothelial cells in 
culture (Astedt & Pandolfi, 1972; Shepro, Schleef, & 
Hechtman, 1980).
The use of exogenous activators to enhance fibri­
nolysis in acute and chronic thrombotic disease has ap­
pealed to many investigators. Streptokinase and uroki­
nase are the two substances most widely used in clinical 
practice, but must be injected and are only useful in 
major acute thrombotic situations. Davidson and Walker 
(1979) and Kwaan (1979) have reviewed various aspects of 
the available synthetic fibrinolytic agents.
Plasmin is produced from plasminogen by the cleavage 
of a single Arg-Val bond (Robbins, Summaria, Hsieh, & 
Shah, 1967). The kinetics of this reaction have been 
recently reviewed by Robbins, Wohl, and Summaria (1981). 
Plasmin is a rather nonspecific protease capable of 
hydrolyzing fibrinogen, prothrombin, and factors V and 
VIII in addition to fibrin. Plasmin is not normally 
detectable in human plasma, probably because of its 
association with circulating inhibitors (Ambrus & Markus, 
1960).
A complex system of fibrinolytic inhibitors is 
believed to play a major role in the regulation and 
control of fibrinolysis. Antiplasmins, such as alpha2-
plasmin inhibitor and alpha2-macroglobulin, are known to 
react with plasmin to form enzymatically inactive 
complexes (Harpel, 1976; Mullertz & Clemmenson, 1976). 
Methods have been presented for the quantitative deter­
mination of these antiplasmins (Harpel, 1981). The 
presence in plasma of antiactivators of plasminogen has 
been described by several investigators (Crutchley, 
Conanan, & Maynard, 1981; Gallimore, 1975; Hedner, 1973), 
but a hypothesis of specific inhibitors of activation has 
not been clearly established (Collen, 1979). Antiplas­
mins, and possibly antiactivators, prevent widespread 
proteolysis and direct the action of plasmin specifically 
to deposits of fibrin.
Although it is generally held that physiological 
fibrinolysis is primarily mediated by the plasminogen- 
plasmin system, it should be recognized that other 
mechanisms independent of plasmin have been postulated 
(Moroz & Gilmore, 1976). Lysis of fibrin by alternate 
proteolytic enzymes such as those in the complement 
system (Goodkofsky & Lepow, 1971) and in the granules of 
leukocytes (Plow & Edgington, 1975), has been described, 
but the importance of non-plasmin-mediated fibrinolysis 
has not been determined.
Measurement of Plasminogen Activator (PA)
The estimation of fibrinolytic activity is primarily 
based on measurement of PA. As fibrinolysis is the net
effect of PA and inhibitors, functional assays for the 
determination of PA should attempt to eliminate the 
effect of inhibitors. The most widely used procedures 
for the measurement of PA are; the diluted clot lysis 
time, the euglobulin lysis time (ELT), and the fibrin 
plate method.
Methods of the whole blood clot lysis time are 
sometimes used as a screening test for hyperfibrinolysis 
(Conrad, 1976), but the presence of inhibitors makes this 
assay far too insensitive and nonspecific to detect 
impaired fibrinolytic activity. Fearnley, Balmforth, and 
Fearnley (1957) have described a method in which fibrino­
lytic inhibitor effects are reduced by dilution. Whole 
blood is diluted in buffer at pH 7.4, clotted with throm­
bin, and incubated at 37 °C. The diluted clot lysis time 
is shorter than that of undiluted blood, and the assay is 
considered to be more specific for measurement of PA.
Greater sensitivity is gained by precipitating the 
euglobulin fraction of plasma, which contains plasminogen, 
plasmin, fibrinogen, and PA (Buckell, 1958). Most 
fibrinolytic inhibitors remain in the supernatant 
and are eliminated. The euglobulin fraction is dissolved 
in buffer, coagulated with calcium, and the time for clot 
lysis is recorded. The ELT is the most commonly used 
assay for PA and is reasonably sensitive and rapid 
(Nordby, Arnsen, Anderson, & Godal, 1980). This method
does, however, vary with the amount of fibrinogen and 
plasminogen in the plasma sample.
Levels of fibrinogen and plasminogen may be 
standardized by using a prepared plate of plasminogen- 
rich fibrin as the substrate (Astrup & Mullertz, 1952). 
After placing the euglobulin fraction of the sample on 
the fibrin plate, fibrinolytic activity is read as the 
circular area of lysis which occurs after incubation. 
The fibrin plate method is the most precise of the 
available functional assays, but it is technically more 
complex and time consuming than the ELT.
A histochemical film technique has been described 
which allows for a direct measure of the vessel PA 
reserve (Pandolfi, 1972). In this method, a biopsy 
specimen is taken, usually from the superficial veins of 
the hand, and the PA content of the vessel wall is 
quantitatively determined.
The capacity of an individual to release PA from the 
vascular endothelium may be assessed by measuring the 
response to various stimuli such as injection of nico­
tinic acid (Robertson, 1971), infusion of vasopressin 
(Aberg & Nilsson, 1975), exercise (Cash, 1968, Cash & 
Woodfield, 1967), or venous occlusion (Clarke, Orandi, & 
Cliffton, 1960; Holemans, 1963; Pandolfi, 1972). Some 
people respond weakly or not at all to such stimuli. 
These individuals are referred to as poor responders and
may be at greater risk for thromboembolic disease (Cash, 
1975).
The measurement of fibrinolytic capacity is believed 
to be a more appropriate technique for studying the 
fibrinolytic enzyme system than simple determinations of 
spontaneous fibrinolysis because of the dynamic state of 
the system and because resting levels of PA must be 
extreme and prolonged to detect subject differences 
(Cash, 1968). Of the available PA release stimuli, 
venous occlusion would appear to be most suitable for 
routine clinical use because it offers highly reproduc­
ible stress and low risk to subjects (Robertson, 
Pandolfi, & Nilsson, 1972). In addition, the ELT has 
been shown to be as reproducible and probably even more 
sensitive than the fibrin plate method after the use of 
venous occlusion (Nordby et al., 1980).
Physiological Fibrinolytic Activity
The view that the fibrinolytic system is continuously 
active is supported by the finding of PA activity in 
normal blood (Mullertz, 1953; Sawyer, Fletcher, Alkjaersig, 
& Sherry, 1960). Levels of spontaneous PA are known to 
fluctuate in any one person from day to day and through­
out the same day (Fearnley, Balmforth, & Fearnley, 1957; 
Rosing, Brakman, Redwood, Goldstein, Beiser, Astrup, & 
Epstein, 1973). Levels of lowest activity are found at 
8:00 a.m., with peak activity between 5:00 and 8:00 p.m.
(Rosing, Brakman, Redwood, Goldstein, Beiser, Astrup, & 
Epstein, 1970). The diurnal variation may be substan­
tially reduced in older individuals (Rosing et al., 
1973).
Release of vascular PA can be dramatically increased 
in response to several naturally occuring events such as 
exercise (Biggs, MacFarlane, & Pilling, 1947; Ogston & 
Fullerton, 1961; Sherry, Lindemeyer, Fletcher, & 
Alkjaersig, 1959) and mental stress and anxiety (Cash & 
Allen, 1967; MacFarlane & Biggs, 1946). The mechanism 
controlling the enhanced release of PA from the endothe­
lial cells has been recently reviewed (Cash, 1978). The 
two main hypotheses are: the action of adrenoceptor
stimulation (Gader, Da Costa, & Cash, 1974) and a change 
in vascular motility (Nilsson & Pandolfi, 1970). These 
theories have been challenged by findings that the rise 
in PA can be only partially prevented by adrenergic beta- 
blockade (Cash, Woodfield, & Allen, 1970) and that 
several potent vasoactive drugs have no effect on PA 
release (Weiner, de Crines, Redisch, & Steele, 1959). On 
the basis of this and other evidence, Cash (1978) has 
suggested that PA release may be under neurohormonal 
control and that endothelial cells may be sensitive to a 
yet unidentified plasminogen activator releasing hormone.
The distribution of vascular activator throughout 
the body is reviewed by Pandolfi (1972). Vessel walls of
small arteries and veins, some large veins, such as the 
renal vein and vena cava, and the lymphatics are found to 
contain PA. Significant venous-arterial differences 
suggest that fibrinolytic activity is considerably higher 
in the microcirculation than in the systemic circulation 
(Holemans, Mann, & Cope, 1967). The activity of the 
microcirculation probably plays an important physiologi­
cal role in maintaining the patency of the capillary bed.
Circulating levels of PA should not be interpreted 
as direct evidence of ongoing fibrinolytic activity. 
Physiological mechanisms must be operating to prevent 
widespread proteolysis. Three theories have been 
proposed for the limitation of plasmin activity specif­
ically to fibrin: plasminogen may be preferentially
adsorbed to fibrin where the effect of inhibitors 
is weak (Alkjaersig, Fletcher, & Sherry, 1959), plasmin 
may have a greater affinity for fibrin than for anti- 
plasmins (Ambrus & Markus, 1960), or PA may be select­
ively bound to fibrin to contact circulating plasminogen 
away from inhibitors (Chesterman, Allington, & Sharp,
1972). These mechanisms, independently or in combina­
tion, could be responsible for the localized digestion of 
fibrin deposits by plasmin in the absence of circulating 
inhibitors. If deposits of fibrin are not in the vascular 
tree, no fibrinolysis will occur despite significant 
release of PA.
Impaired Fibrinolytic Activity
More than a century ago, von Rokitansky (1854) 
proposed that deposits of fibrin were the initiating
I
lesions of arteriosclerosis. This concept was reviewed 
by Duguid in 1946 when he observed that many of the 
lesions which were classified as atherosclerotic were 
actually the result of excess arterial fibrin deposition. 
Astrup (1956) expanded this idea by suggesting the 
existence of a dynamic equilibrium between coagulation 
and fibrinolysis.
Investigators have studied components of the 
fibrinolytic system to determine if impaired fibrinolytic 
activity might be an etiological factor in occlusive 
vascular disease. The largest body of evidence concerns 
relationships between low fibrinolysis (as judged by low 
spontaneous PA levels, reduced capacity for release of 
PA, or low vessel wall PA content) and the presence of 
venous and arterial thromboembolic complications. Many 
studies have demonstrated impaired fibrinolytic activity 
in patients with venous thrombosis (Clayton, Anderson, & 
McNicol, 1976; Gordon-Smith, Hickman, & Le Quesne, 1974; 
Isacson & Nilsson, 1972; Mansfield, 1972). Reduced 
fibrinolysis is also associated with occlusive arterial 
disease (Mettinger, Nyman, Kjellin, Siden, & Soderstrom, 
1979; Nestel, 1959).
There is available evidence in support of the
atherogenic consequences of impaired fibrinolytic 
activity. Defective fibrinolysis can be demonstrated in 
patients with coronary heart disease (Chakrabarti, 
Hocking,-Fearnley, Mann, Attwell, & Jackson, 1968; Rosing 
et al.f 1973; Walker, Davidson, & Hutton, 1976). A 
reduction in fibrinolytic activity is also reported in 
association with most risk factors for atherosclerosis 
including hypertension (Tsapogas, Peabody, Kwang-Tzen, 
Devaraj, & Eckert, 1974), cigarette smoking (Billimoria, 
Pozner, Metselaar, Best, & James, 1975; Dalderup, Zwartz, 
Keller, Schouten, & van Haard, 1970) , elevated levels of 
cholesterol and triglycerides (Connor, Hoak, & Warner, 
1963; O'Brien, 1957), obesity (Aimer & Janzon, 1975; 
Bennett, Ogston, McAndrew, & Ogston, 1966) , and diabetes 
mellitus (Aimer & Nilsson, 1975; Wilkens & Back, 1978).
Several investigations have produced evidence which 
is more indicative of a causal relationship between 
impaired fibrinolysis and vascular disease than the 
associational studies mentioned above. Pharmacological 
enhancement of fibrinolysis has been shown to improve the 
clinical condition of patients which an increased 
tendency toward thromboembolic disorders (Bielawiec, 
ffysliwiec, & Perzanowski, 1978; Cunliffe, Roberts, & 
Dodman, 1973; Hedner, Nilsson, & Isacson, 1976; Nilsson, 
Nilsson, & Hedner, 1981). Experimental studies have 
shown that vascular complications can be produced by
decreasing fibrinolytic activity with diet in the rat 
(Naimi, Goldstein, Nothman, Wilgram, & Proger, 1962) and 
by pharmacologically increasing levels of inhibitors in 
the rabbit (Kwaan & Astrup, 1964).
Summary
Components and mechanisms for the enzymatic removal 
of fibrin have been reviewed. Although several mechanisms 
have been identified, it is generally accepted that the 
extrinsic pathway of the plasminogen-plasmin system is 
the dominant mechanism in physiological fibrinolysis.
Synthesis and release of PA by the vascular endothelium
appears to be the critical step in this pathway. It was 
concluded that fibrinolytic activity could best be 
estimated by the measure of PA levels.
Available techniques for PA determination were 
presented. Fibrinolysis can be assessed by measures of 
spontaneous fibrinolysis, fibrinolytic capacity, or 
vessel wall PA content. The ELT assay of the PA response 
to venous occlusion is rapid, simple, reasonably 
sensitive, and appears to be particularly well suited for 
clinical investigations of fibrinolytic capacity.
Various aspects of physiological and impaired
fibrinolytic activity were discussed. Physiological
fibrinolysis demonstrates diurnal variation and may be 
affected by exercise and emotional stress. It has been 
postulated that a balance must be maintained between
coagulation and fibrinolysis to avoid pathological 
changes associated with excess fibrin deposition. The 
importance of normal fibrinolytic activity has been 
inferred from relationships between impaired fibrinolysis 
and thrombotic or atherosclerotic disease.
Diabetes Mellitus
Vascular disease plays a major role in the morbidity 
and mortality of diabetes mellitus. The classification 
of diabetes mellitus indicates that blood glucose 
concentrations are above acceptable standards, but 
heterogeneous metabolic and biochemical abnormalities may 
be present in a population identified solely on the basis 
of hyperglycemia. For decades, researchers have argued 
the importance of strict blood glucose control in the 
delay or prevention of diabetic vascular complications, 
but until the recent availability of glycosylated 
hemoglobin, this controversy has been plagued by the lack 
of a reliable index of metabolic control (Raskin, 1978).
Disturbances in the systems regulating hemostatic 
balance are among the possible etiological factors in the 
development of diabetic angiopathy. A number of investi­
gations support the hypothesis that diabetic patients 
face an increased tendency for hypercoagulation (Jones & 
Peterson, 1981a, 1981b). Studies of fibrinolytic activity 
in diabetes mellitus have yielded conflicting reports. 
Preliminary evidence indicates that vascular complications
may be reduced by improved metabolic control. It has 
also been suggested that variation in diabetic fibrin­
olysis may be explained by differences in control of 
blood glucose (Gunnarson, Nyman, Walinder, & Ostman, 
1980).
Heterogeneity of the Syndrome
Diabetes mellitus affects more than 10,000,000 
Americans and is the third ranking cause of death in this 
country (Scope and Impact of Diabetes, 1976). Recent 
research has clearly indicated that diabetes is not one 
disease, but a heterogeneous group of syndromes with a 
variety of genetic and environmental causes (Fajans, 
Cloutier, & Crowther, 1978; Nerup & Lernmark, 1981; 
Rotter & Rimoin, 1981). The diagnosis of diabetes 
mellitus implies the expression of hyperglycemia, but 
reveals nothing about the metabolic and biochemical 
abnormalities that may be present.
The heterogeneous nature of diabetes mellitus has 
led to confusion and inconsistencies in the reporting of 
diabetes research. The National Diabetes Data Group 
(1979) has done much to solve this problem by reaching an 
international consensus regarding the clinical and diag­
nostic classification of glucose intolerance disorders. 
This workgroup has made specific recommendations for the 
collection of clinical and research data.
Historically, diabetes has been thought to be a
disease of insulin deficiency. The two major subgroups 
of clinical diabetes mellitus have been classified by the 
National Diabetes Data Group (1979) primarily on their 
dependence on exogenous insulin to sustain life. 
Insulin-dependent diabetes mellitus (IDDM, type I, 
formerly juvenile-onset) is characterized by an absolute 
deficiency of insulin with an essential dependence on 
injected insulin and a proneness to ketosis. Non-insulin- 
dependent diabetes mellitus (NIDDM, type II, formerly 
maturity-onset) is characterized by significant insulin 
production, but in quantities insufficient to maintain 
normal glucose homeostasis. Research has shown that IDDM 
and NIDDM are different pathological entities, rather 
than simple gradations of insulin deficiency.
Endogenous insulin is negligible in the type I 
diabetic. Insulin secretion, as determined by C-peptide 
measurements, is generally not detectable in individuals 
with IDDM who have received insulin therapy for more than 
five years (Block, Mako, Steiner, & Rubenstein, 1972). 
Because insulin is the primary factor which controls the 
storage and metabolism of ingested nutrients, an absolute 
deficiency of insulin results in inadequate disposal of 
foodstuffs (glucose intolerance) and excessive mobiliza­
tion or production of endogenous fuels (fasting hypergly­
cemia, hyperaminoacidemia, and elevated free fatty 
acids). In its most severe form, there is a marked
acceleration of all catabolic processes, which produces 
diabetic ketoacidosis (DKA).
Attention to diet and exercise, with the systematic 
injection of insulin, are the standard therapeutic mea­
sures taken to normalize blood glucose levels in IDDM 
(Treatment of Diabetes, 1976). In recent years, several 
innovative programs of insulin administration have 
reported close approximation of physiological homeostasis 
(Skyler, Seigler, & Reeves, 1982; Skyler, Skyler, 
Seigler, & O'Sullivan, 1981; Tattersall & Gale, 1981), 
but true euglycemia has only been achieved with special 
research instruments capable of infusing insulin on the 
basis of feedback from glucose sensors (Botz, Marliss, & 
Albisser, 1979; Service, Rizza, Westland, Hall, Nelson, 
Haymond, Clemens, & Gerich, 1980). Conventional therapy 
consists of single or multiple injections of insulin on a 
daily basis. The matching of injected insulin to metabolic 
need is a mere approximation, even with the newer modes 
of therapy, and intermittent hyperglycemia is relatively 
unavoidable (Peterson, 1982).
NIDDM accounts for more than 80% of the cases of 
diabetes in the United States, and the large majority of 
these patients are obese at the time of their diagnosis 
(Bennett, 1981). Obesity is thought to contribute to a 
state of insulin resistance often seen in the type II 
diabetic (Kolterman, Heaven, & Olefsky, 1979; Olefsky,
1976; Olefsky & Kolterman, 1981). Basal Insulin levels 
are typically normal or even increased in NIDDM, but 
glucose stimulated insulin secretion is generally dimin­
ished (Olefsky & Reaven, 1977). Glucose homeostasis 
cannot be maintained with the insulin resistance of 
NIDDM, but there are generally less marked fluctuations 
in blood glucose levels than are seen in IDDM, and DKA is 
very rare.
Therapy for the obese diabetic usually involves a 
diet restricted in calories and an increase in physical 
activity (Treatment of Diabetes, 1976). These measures 
have been shown to improve insulin sensitivity (Davidson, 
1976; Soman, Koivisto, Diebert, Felig, & DeFronzo, 1979). 
If diet and exercise are not effective in maintaining 
metabolic control in NIDDM, it may be necessary to pre­
scribe oral hypoglycemic drugs or insulin.
Glycosylated Hemoglobin and Metabolic Control
It has been argued for years that insulin deficiency 
and its metabolic consequences are the fundamental 
etiological factors in the pathogenesis of diabetic 
complications (Raskin, 1978). The major problem in 
attempting to relate hyperglycemia to the development of 
long-term complications has been the availability of a 
valid and reliable method of assessing chronic metabolic 
control. Glucose values are found to undergo wide 
fluctuations from hour to hour and from day to day in
diabetes (Molnar, Taylor, & Ho, 1972). Little or no 
correlation may exist between blood glucose 
concentrations obtained during a clinic visit and values 
obtained throughout a diabetic's normal day (Rifkin, 
1978; Tchobroutsky, 1978). Monitoring of glycosuria,
fasting blood glucose, and glucose tolerance tests cannot 
be used as valid estimates of long-term control, and 
serial measures of blood glucose concentrations have been 
plagued by problems of sampling frequency (Molnar, 
Marien, Hunter, & Harley, 1979).
Glycosylated hemoglobin is a variant of normal adult 
hemoglobin (HbAl). It has been shown to be elevated with 
chronic hyperglycemia and correlates closely with the 
average blood glucose concentration over several weeks 
(Gonen, Rubenstein, Rochman, Tanega, & Horowitz, 1977; 
Paisey, MacFarlane, Sherriff, Hartog, Slade, & White, 
1980). Total HbAl is composed of several minor variants 
(HbAlal, HbAla2, HbAlb, and HbAlc) which are formed 
slowly and continuously throughout the life span of the 
red cell (Bunn, Haney, Kamin, Gabbay, & Gallop, 1976). 
Thus, levels of HbAl should provide a measure of the mean 
blood glucose level over the preceeding two to three 
months (Gabbay et al., 1977).
Allen, Schroeder, and Balog (1958) first identified 
the minor components of normal adult hemoglobin as the 
fast-moving fraction in a chromatographic system using a
cation-exchange resin. Total HbAl was found to comprise 
about 7% of total hemoglobin, with HbAlc, the major 
component, representing 5-6% of the total. Hemoglobin 
Ale is formed by the attachment of glucose to the 
N-terminal valine of the beta chain (Bookchin & Gallop, 
1968) and the chemical steps involved in this synthesis 
have been well defined (Higgins & Bunn, 1981).
A variety of techniques are available for the deter­
mination of HbAl (Bunn, 1981). The original technique of 
isolation by column chromatography is recognized as the 
standard and is most widely used (Allen et al., 1958). 
Metabolic control of diabetes may be reported as HbAlc, 
or as total HbAl. While HbAlc can be elevated as much as 
three fold in diabetic red cells (Huisman & Dozy, 1962; 
Paulsen, 1973) , the concentrations of the remaining 
components appear to be normal in diabetes (McDonald, 
Shapiro, Bleichman, Solway, & Bunn, 1978). Thus, eleva­
tions in HbAl are thought to reflect changes in HbAlc.
Recently, a labile form of glycosylated hemoglobin 
has been identified which is chromatographically 
indistinguishable from HbAlc (Goldstein, Peth, England, 
Hess, & Da Costa, 1980). If this labile fraction is not 
removed, the concentration of glycosylated hemoglobin may 
change significantly over a period of hours. To use HbAl 
as an accurate index of long-term glucose control, it is 
necessary to remove the labile material by incubation of
erythrocytes in saline at 37°C prior to column chromato­
graphy (Compagnucci, Cartechini, Bolli, De Feo, 
Santeusanio, & Brunetti, 1981; Goldstein, Parker, 
England, Wiedmeyer, Rawlings, Hess, Little, Simonds, & 
Breyfogle, 1982).
Hypercoagulation in Diabetes Mellitus
Available therapeutic measures have not prevented 
the development of chronic diabetic complications 
affecting the eyes,, nerves, kidneys, and arteries. 
Vascular pathology is the central focus for many of these 
complications and is generally divided into two major 
categories; microangiopathy, which is an alteration of 
the small blood vessels; and macroangiopathy, which is an 
involvement of the large vessels. Extensive reviews are 
available for the clinical manifestations of diabetic 
microvascular (McMillan, 1975) and macrovascular (Ganda, 
1980) disease. The role of hyperglycemia in the 
biochemical alterations is presented by Brownlee and 
Cerami (1981) .
Although it should be recognized that diabetic 
angiopathy is probably multifactorial in origin, increas­
ing attention is being paid to abnormal hematological 
alterations in the pathogenesis of micro- and macrovas­
cular disease (Jones & Peterson, 1981a, 1981b). Histolo­
gical studies show that vascular lesions in diabetes 
(Davies, Woolf, & Carstairs, 1966; Farguhar, MacDonald, &
Ireland, 1972) and atherosclerosis (Haust, Wyllic, & 
Moore, 1965) contain large deposits of fibrin. Findings 
of increased platelet adhesion (Fuller, Keen, Jarrett, 
Omer, Meade, Chakrabarti, North, & Stirling, 1979; 
Sharma, 1981), increased coagulation factors (Gensini, 
Abbate, Favilla, & Serneri, 1979; Fuller at al., 1979; 
Mayne, Bridges, & Weaver, 1970), and elevated fibrinogen 
levels (Coller at al., 1978; Wardle, Piercy, & Anderson,
1973) suggest the possibility of a hypercoagulable state 
in diabetes. This theory is further supported by reports 
of increased fibrinogen turnover (Bannerjee, Sahui, & 
Kumar, 1973; Ferguson, Mackay, Phillip, & Sumner, 1975).
Recent investigations indicate that hypercoagulation 
is related to levels of HbAl (Coller et al., 1978; Sowers 
et al., 1980). Clinical studies demonstrate that
platelet function (Peterson, Jones, Koenig, Melvin, &
Lehrman, 1977) and fibrinogen turnover (Jones & Peterson, 
1979) can be normalized by reduction in HbAl. These 
findings suggest that increases in blood glucose
concentrations are associated with states of hypercoagu­
lability and thus, increased fibrin deposition.
Fibrinolysis in Diabetes Mellitus
Unneeded deposits of fibrin are normally removed 
from the vascular tree by activity of the fibrinolytic 
enzyme system. A hypercoagulable state should, there­
fore, be compensated for by enhanced fibrinolytic activity.
Although investigations consistently demonstrate increased 
coagulation in diabetes mellitus, there is no such 
agreement concerning fibrinolysis. Findings have been 
plagued by inconsistent methodologies and inadequate 
classification of diabetic subjects.
Single sample analysis techniques of spontaneous PA 
levels have been criticized for their inability to 
identify states of impaired fibrinolysis because of the 
normal variation in fibrinolytic activity found both 
within and between subjects (Cash, 1968). Investigations 
of spontaneous fibrinolysis in diabetes are so controver­
sial that it would be difficult to base conclusions on 
the available reports. Increased (Bern, Cassani, Horton, 
Rand, & Davis, 1980; Cash & McGill, 1969), normal 
(Denborough & Paterson, 1962; MacKay & Hume, 1964), and 
decreased (Fearnley, Chakrabarti, & Avis, 1963; Badawi, 
El-Sawy, Mikhail, Nomeir, & Tewfik, 1970) spontaneous 
fibrinolysis is reported in the literature.
Several investigators have examined differences in 
spontaneous fibrinolysis within subgroups of diabetic 
patients. Sharma (1981) found activity to be significant­
ly increased in type I diabetics and decreased in type II 
diabetics when compared to controls. Aimer and Nilsson 
(1975) reported no differences in type I and type II 
diabetics, but there was a correlation between impaired 
fibrinolysis and obesity. Aimer, Pandolfi, and Nilsson
(1975) found the spontaneous fibrinolytic activity to be 
decreased in diabetics with retinopathy compared to those 
who had not developed retinopathy. Bern et al. (1980) 
found essentially no differences between nonobese groups ’ 
of type I diabetics without retinopathy, type I diabetics 
with retinopathy, and type II diabetics with atherosclero­
sis, although all values were higher than in controls.
Studies of PA release capacity and vessel PA content 
have provided more consistent results. The diabetic 
response to exercise (Cash & McGill, 1969; Seth, 1973) 
and venous occlusion (Aimer & Nilsson, 1975) is depressed 
and the PA content of the vessel wall is lower in diabetics 
than in controls (Aimer et al., 1975). No significant 
difference was found, however, in the fibrinolytic re­
sponse to adrenaline in diabetics and nondiabetics 
(Tanser, 1967). The inability to detect differences in 
this investigation may have resulted from the use of the 
less sensitive diluted clot lysis assay.
Aimer et al. (1975) found differences in fibrin­
olytic capacity to be related to the presence of retinop­
athy, and Aimer and Nilsson (1975) found a significant 
correlation between depressed capacity for fibrinolysis 
and obesity. Diabetic subjects were not examined on the 
basis of insulin dependency. Cash and McGill (1969) and 
Seth (1973) examined "young" diabetics (19-30 yr) and 
newly diagnosed maturity-onset diabetics (26-55 yr)
respectively, and both studies produced similar data. No 
attempt was made to explain variations found within the 
diabetic groups.
Gunnarson et al. (1980) established a relationship 
between HbAl and fibrinolytic capacity, but a very 
heterogeneous group of diabetic subjects, and two healthy 
controls, were used in this investigation. Diabetics 
ranged in age from 18 to 75 yrs and therapy consisted of 
diet only, diet and oral hypoglycemics, or insulin. It 
is possible that variation in fibrinolytic capacity could 
have been explained by a variety of factors such as age, 
obesity, etc., but no systematic attempt to examine these 
variables was reported.
Summary
The heterogeneous nature of diabetes mellitus has 
been reviewed. Two main subclasses, IDDM and NIDDM, have 
been identified by the National Diabetes Data Group 
(1979). Patients with type I and type II diabetes differ 
primarily in production of endogenous insulin. Type II 
diabetes is closely associated with obesity, and a study 
which contains subjects with NIDDM may be affected by a 
variety of factors commonly found in normal obese popula­
tions, in addition to chronic hyperglycemia.
The metabolic basis of diabetic vascular disease has 
been difficult to investigate because of a lack of a 
reliable index of longterm blood glucose control. The
recent availability of HbAl assays now provides a means 
to establish relationships between metabolic control and 
various hematological abnormalities and complications of 
diabetes.
Studies of the hemostatic mechanisms in diabetes 
have been reviewed. Evidence favors the hypothesis of a 
hypercoagulable state which is associated with chronic 
hyperglycemia. Studies of the fibrinolytic system in 
diabetes are very controversial. Conflicting reports 
have come from investigations which have looked at 
spontaneous fibrinolysis. Studies which have used the 
ELT, the fibrin plate method, or determination of vessel 
wall PA content, agree that the capacity for release of 
PA from the endothelium is reduced in diabetes mellitus, 
but levels of activity are found to vary among diabetic 
patients. Obesity and diabetic vascular disease may 
account for some of the differences in fibrinolytic 
capacity. A preliminary investigation suggests that 
different levels of metabolic control may also be a 
source of fibrinolytic variation, but further study is 
needed.
CHAPTER III 
METHODS 
Subjects
Twenty-six (nine males, 17 females) subjects with 
IDDM, and 20 (nine males, 11 females) healthy controls 
were examined. Diabetic subjects were selected from 
cases seen in the Diabetes Management Clinic at Earl K. 
Long Memorial Hospital, Baton Rouge, Louisiana. Documen­
tation of IDDM was bas^d on criteria developed by the 
National Diabetes Data Group (1979). The subjects were 
informed of the nature of the study before commencement 
Of testing and were asked to sign a consent form in 
accordance with the Human Use Committee at Louisiana 
State University (Appendix B). Clinical and 
anthropometric data for subjects by group are presented 
in the Results.
Procedures
All subjects were tested between the hours of 7:00 
and 9:00 a.m., following an overnight fast. Diabetic 
subjects were instructed to follow their usual schedule 
for insulin injection. No subject had smoked cigarettes 
or engaged in vigorous exercise the morning of the inves­
tigation.
Samples of venous blood were collected before and 
after venous occlusion and were subsequently assayed for 
ELT, HbAl, serum glucose (GLU), cholesterol (CHO), and
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triglyceride (TRI). Diabetic subjects were tested at 
Earl K. Long Memorial Hospital under the supervision of 
Glen Johnson, M.D., with technical assistance by Phyllis 
Sauchier, R.N.
Blood Collection
Approximately 8 ml of blood were withdrawn by direct 
venepuncture into chilled 10 ml plastic syringes for pre- 
and post-occlusion samples. The pre-occlusion sample was 
taken with a minimum of stasis (pressure below diastolic 
for less than 30 sec) from an antecubital vein in one 
arm. A sphygmomanometer cuff was placed around the 
contralateral arm and blood pressure was determined. The 
cuff was then inflated to a pressure midway between 
systolic and diastolic blood pressure and was maintained 
for 10 min. At the end of minute 10, the post-occlusion 
sample was collected from an antecubital vein distal to 
the cuff, and the cuff was deflated.
Euglobulin Lysis Time (ELT)
Immediately following blood collection, 2.25 ml of 
the sample were transferred to a 15 ml polypropylene 
centrifuge tube containing 0.25 ml sodium oxalate, 1.34%, 
that had been previously chilled to 5°C. The tubes were 
then placed in melting ice to await centrifugation. 
Plasma was separated by centrifugation at 3,000 x g for 
15 min within 30 min of collection.
Two 15 ml polypropylene centrifuge tubes per sample
were prepared the day before testing for subsequent 
dilution and acidification of plasma. The tubes, 
containing 9 ml distilled water and 0.1 ml 1% acetic 
acid, had been chilled overnight in a refrigerator at 
5°C.
Following centrifugation, 0.5 ml of plasma were 
pipetted into the prepared tubes. The tubes were covered 
with Parafilm and placed in a refrigerator at 5°C for 30 
min to allow precipitation of the euglobulin fraction. 
The tubes were then centrifuged for 5 min at 3,000 x g. 
The supernatant was decanted by inverting the tubes and 
draining on filter paper.
The precipitate was resuspended in 0.5 ml borate 
solution (0.9 g sodium chloride + .1 g sodium borate made 
to 100 ml with distilled water) and stirred gently with a 
glass rod. The tubes were then placed in a water bath at 
37°C for 5 min. Calcium chloride (0.025M), 0.5 ml, was 
then added and the time was recorded.
The tubes were inspected at regular intervals until 
complete clot lysis had occurred. The ELT was recorded 
as the difference in minutes from addition of CaClj to 
complete lysis. The mean for the duplicate 
determinations was calculated. These procedures, with 
minor modifications, were described by Buckell (1958).
The ELTs were used to compute FC using the formula: 
(A - B)/A x 100 - FC 
where A and B respectively represent pre- and post­
occlusion ELT's.
Glycosylated Hemoglobin (HbAl)
For analysis of HbAl, 2.5 ml of the pre-occlusion 
sample were emptied into a chilled tube of 3% EDTA and 
stored at 5°C. Samples were assayed in duplicate within 
two days of collection. A Glycosylated (Fast Fraction) 
Hemoglobin Quick Column Kit (Helena, cat. no. 5340) was 
used to measure HbAl, ‘ and the procedures of the Total 
Fraction Method were followed. For quality control 
purposes, Lyophilized G-Hb Quick Column Control (Normal) 
(Helena, cat. no. 5347) and Lyophilized G-Hb Quick Column 
Control (Abnormal) (Helena, cat. no. 5348) were assayed 
with each determination.
Prior to performing column chromatography, the 
following procedures were utilized to remove the labile 
fraction of HbAl. The red blood cells were washed three 
times with saline (0.85%), and the saline was decanted. 
The washed packed cells were then incubated at 37°C for 
four hours. Samples were then prepared by placing 310 yL 
of Hemolysate Reagent-C into a small test tube containing 
10 yL of packed red blood cells. Sample preparations 
were shaken to produce complete hemolysis and were 
allowed to stand for 5 min. All columns and reagents 
were at room temperature and this temperature was 
recorded.
Glycosylated hemoglobin was determined by placing
lOOyL of sample preparation in a Helena Quick Column and 
an additional 100 yL of the same preparation in a large 
collection tube. A small collection tube was placed 
under the Quick Column. Following absorption of the 
sample into the resin bed of the column, 15 ml of Fast 
Fraction Developer were added to elute the HbAl. The 
eluted fraction was referred to as the fast fraction 
(FF) . The FF was made to 3 ml in the small collection 
tube with purified water. The 100 yL sample in the large 
collection tube was made to 15 ml with purified water and 
was referred to as the total fraction (TF).
A spectrophotometer set at 415 nm was used to deter­
mine the optical density (OD) of both the FF and TF. The 
following formula was used to calculate the percentage of 
HbAl for each sample:
5TOE bfwv * 100 -
Values obtained were adjusted with the Helena 
Temperature/G-Hb Conversion Chart if room temperature was 
not 22°C at the time of HbAl determination. The mean for 
duplicate determinations was calculated.
Serum Glucose (GPU) „ Cholesterol (CHO), and Triglyceride (TRI)
Approximately 3 ml of the pre-occlusion sample were 
emptied into a chilled glass tube, placed on ice, and 
allowed to clot. Serum was removed by centrifugation for 
10 min at 3,000 x g. Determinations of GLU, CHO, and TRI
were performed on a Coulter Chemistry Analyzer using 
standard Earl K. Long Clinical Chemistry Laboratory 
procedures.
Statistical Analysis
Three major approaches for data analysis were 
utilized. First, t-tests were made between the diabetic 
and control groups for FC, HbAl, CHO, TRI, GLU, and other 
variables. Secondly, simple bivariate correlations 
between variables were calculated for diabetic subjects 
only, for normal controls only, and for the entire 
subject cohort. Finally, multiple linear regression with 
a stepwise solution was utilized to examine the 
contribution of HbAl, CHO, TRI, and GLU as explanatory 
variables for FC. Each independent variable was forced 
into the analysis during separate runs to examine their 
importance when entered first, and also with other 
variables already in the statistical model. A calculated 
probability of .05 or less was taken as the index of 
statistical significance.
CHAPTER IV 
RESULTS
Characteristics of Subjects and Group Differences 
Clinical and anthropometric data for subjects by 
group are presented in Table 1. No significant differ­
ences were found to exist between diabetics and the 
normal controls for age _(t *= 1.661, £ = .104), height (t 
= 1.479, £  = .148), or weight (t = 1.549, £ « .130), 
which supports the assumption that groups were 
appropriately matched for these variables. Raw data for 
diabetics and controls are included in Appendices C and 
D, respectively.
TABLE 1
Clinical and Anthropometric Data for Subjects by Group
Group n Age
(yrs)
Height
(cm)
Weight
(kg)
Duration of 
Diabetes 
(yrs)
Insulin Dose 
(U/24 hrs)
Diabetic 26 25.3 165.7 59.9 9.4 48.0
±6.8 ±8.0 ±11.8 ±4.3 ±21.9
Non- 20 28.4 169.7 65.9
Diabetic ±5.4 ±9.5 ±14.0
Note. Values are M 1 SD.
Mean values for FC, HbAl, GLU, CHO, and TRI for 
diabetics and nondiabetics are given in Table 2. 
Significant differences were found between groups for FC
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(t = 3.786, £ = .0005), HbAl (t = 8.305, £ = .0001), GLU 
(t = 5.710, £ ■ .0001), and CHO (t «= 2.325, P = .026). 
No significant differences were seen for TRI (t *= 1.615, 
£  = .116). Raw scores for diabetics and controls are 
included in Appendices E and F, respectively.
TABLE 2
Fibrinolytic Capacity (FC), Glycosylated Hemoglobin 
(HbAl), Serum Glucose (GLU), Cholesterol (CHO), and 
Triglyceride (TRI) for Diabetics and Nondiabetics
Group FC HbAl GLU CHO TRI
(%) (%) (mg%) (mg%) (mg%)
Diabetic
M 46.6 10.3 209 215 78
SD ±19.3 ±2.1 ±102 ±56 ±60
n 26 26 26 25 24
Nondiabetic
M 64.2 6.5 95 186 56
SD ±12.1 ±.9 ±7 ±25 ±24
n 20 19 19 20 19
Bivariate Correlations 
Bivariate correlations between variables for diabetic 
subjects are presented in Table 3. A significant inverse 
correlation was found to exist between FC and TRI (r = 
-.45, £ = .029), but FC and HbAl (r « -.08, £ = .713)
were not statistically related. A positive relationship 
was found for HbAl and CHO (r = .59, £  *= .002), but
correlations were not significant for HbAl and GLU (r =
.35, £  - .084) or HbAl and TRI (r = .24, £  = .249) . No
significant relationship was found for FC and CHO (r =
.24, £ = .883).
TABLE 3
Bivariate Correlations for Diabetic Subjects
FC HbAl GLU CHO TRI
FC -.08 .32
.71 .11 
26 26
.03
.88
24
-.45
.03
24
HbAl .35
.08
26
.59
.002
25
.24
.25
24
GLU .13
.54
25
-.25
.25
24
CHO .39
.06
23
Note. Values are r, bivariate correlation; £, calculated 
probability; n, sample size.
For nondiabetic subjects (Table 4), FC was again 
inversely related to TRI (r *= -.51, £  *= .027). Unlike
diabetic subjects, the normal controls showed a signif­
icant positive relationship between FC and HbAl (r *= .54, 
£ = .017).
TABLE 4
Bivariate Correlations for Nondiabetic Subjects
FC HbAl GLU CHO TRI
.54 .003 -.33 -.51
FC .02 .99 .15 .03
19 19 20 19
-.25 -.15 -.45
HbAl .31 .53 .05
18 19 19
.19 .18
GLU .43 .48
19 18
.19
CHO .44
19
Note. Values are r, bivariate correlations; £,
calculated probability; n, sample size.
The combined sample (Table 5) demonstrated the same 
inverse relationship between FC and TRI (r = -.49, £ = 
.0008) found for diabetics and nondiabetics alone. A 
significant inverse correlation was also found for FC and 
HbAl (r «= -.33, £  *= .026) in the combined sample, a
finding that conflicts with data for diabetics only.
TABLE 5
Bivariate Correlations for Diabetics 
and Nondiabetics Combined
FC HbAl GLU CHO TRI
FC
-.33
.03
45
-.09
.57
45
-.18
.24
45
-.49
.0008
43
HbAl
.61
.0001
44
.0002
44
.27
.07
43
GLU
.28
.07
44
-.05
.74
42
CHO
.40
.0008
42
Note. Values are r, bivariate correlation; £, calculated 
probability; n, sample size.
Regression Analysis 
Regression analysis of the stepwise linear 
regression for diabetic data suggests that the most 
powerful predictor of FC in insulin-dependent diabetes is 
the level of serum triglyceride (Table 6). TRI was 
significant when entered first (ARa «= .200) into the
model, and when entered after CHO (ARa = .226). No other 
variable was significant when entered after TRI. HbAl
44
was not found to be significant when entered first (ARa = 
.021).
TABLE 6
Summary of Stepwise Linear Regression Analysis for Diabetic Data 
With Fibrinolytic Capacity as the Dependent Variable
Step Variable AR2 Probability
1 TRI
Run 1
.200 .03
2 HhAl .001 .84
3 GLU .000 .12
4 CHO .041 .30
1 HhAl
Run 2
.021 .46
2 GLU .205 .03
3 CHO .011 .59
4 TRI .103 .11
1 CHO
Run 3
.001 .90
2 TRI .226 .02
3 HhAl .024 .43
4 GLU .090 .13
1 GLU
Run 4
.139 .07
2 CHO .007 .67
3 TRI .132 .07
4 HhAl .063 .21
CHAPTER V 
DISCUSSION 
Introduction
It has been hypothesized that impaired fibrinolysis 
may contribute to diabetic vascular complications. Many 
investigators have examined fibrinolytic activity in 
diabetes, but conflicting results have been produced 
because of inconsistent methodologies and inadequate 
classification of diabetic ,subjects. To avoid these 
problems, a standardized measure of fibrinolytic capacity 
(FC) was used in this study to examine the relationship 
between metabolic control and FC in subjects meeting the 
criteria for clinical classification of insulin-dependent 
diabetes mellitus (IDDM).
Fibrinolytic Capacity in Insulin-Dependent Diabetes Mellitus 
The data from this research suggest that insulin- 
dependent diabetics have a reduced capacity for fibrin­
olysis when compared to healthy controls. This finding 
concurs with Aimer and Nilsson (1975), Aimer, Pandolfi, 
and Nilsson (1975), and Cash and McGill (1969), but is at 
variance with Tanser (1967) who found normal responses to 
subcutaneous injection of adrenaline. While there is a 
possibility that the response to adrenaline injection in 
diabetes would differ from that produced by venous 
occlusion or exercise, no differences are seen in healthy 
subjects (Cash & Allan, 1967; Hedner & Nilsson, 1981).
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A more plausible explanation for the conflicting 
finding of Tanser (1967) is the wide range of diabetic 
conditions included in his study. A heterogeneous 
diabetic group may present divergent intervening 
variables which may affect FC. Previous investigations 
showing reduced FC in diabetes have chosen to classify 
subjects on the basis of age at onset (juvenile- vs. 
maturity-onset). However, The National Diabetes Data 
Group (1979) has pointed out that age at onset does not 
necessarily determine insulin-dependency. Existing 
papers which have investigated fibrinolytic activity in 
documented IDDM have measured only spontaneous fibrin­
olysis (Bern et al., 1980; Sharma, 1981). Thus, the
present report is unique in that FC has now been examined 
in IDDM.
Fibrinolytic Capacity and Metabolic Control 
Data from the present study do not support a rela­
tionship between FC and HbAl for insulin-dependent 
diabetics. However, it may be of interest to note that a 
significant negative correlation was observed (r = -.33) 
when normals and diabetics were combined into a single 
sample. The relationship for the combined sample was 
remarkably similar to that reported by Gunnarsson, et al 
(1980), r «= -.35, who also combined normal and diabetic 
data for statistical analysis. These data, as well as 
those which show large group differences in GLU, CHO,
TRI, and HbAl, suggest that it is inappropriate to 
include normal subjects when attempting to make statements 
concerning glucose homeostasis among diabetic individuals. 
It appears that differences between normals and diabetics 
act as intervening variables to confuse or totally 
distort the relationship between FC and metabolic control 
if a combined sample of diabetics and controls is utilized 
for statistical analysis.
The statistically significant positive relationship 
between FC and HbAl for normals is interpreted as a 
chance occurrence and probably has no clinical or physio­
logical significance. This interpretation is based on 
the assumption that the slope of the relationship has no 
theoretical basis and also on the assumption that the 
homogeneous grouping of HbAl for the normal sample could 
contribute to the unexpected statistical outcome.
Intervening Variables Affecting Fibrinolytic Capacity
A significant proportion of variance in FC for 
insulin-dependent diabetics in the present investigation 
is explained by levels of serum triglyceride. For many 
years, lipids have been recognized as having an inhibitory 
effect on fibrinolysis (Merskey & Markus, 1963), but 
precise mechanisms have not been identified. It is 
evident that there is no simple relationship between 
lipids and fibrinolysis, as divergent results are produced 
by several different lipid abnormalities (Brakman,
Astrup, Levy, & Fredrickson, 1974).
Hyperlipidemia is a common finding in diabetes, but 
there appears to be a complex interaction between the 
diabetic syndrome, the genetic background of the individu­
al, and the environment (Goldberg, 1981). In IDDM, 
several investigations have shown that lipid abnormalities 
can be related to metabolic control (Glasgow, August, & 
Hung, 1981; Pietri, Dunn, Grundy, & Raskin, 1983? Sosenko, 
Breslow, Miettinen, & Gabbay, 1980). Results from the 
present study lend partial support to these findings in 
that a significant correlation was found between HbAl and 
CHO (r = .59), but not between HbAl and TRI (r = .24). 
Factors other than HbAl, which may have affected TRI 
levels, include uncontrolled dietary factors, genetic 
hyperlipidemia, or the presence of diabetic glomeruloscle­
rosis (Tattersall, 1982).
Aimer and Nilsson (1975) found impaired FC to be 
closely associated with the presence of microvascular 
disease. The present investigation, however, was unable 
to place any statistical significance on documented 
vascular complications. This should not rule out the 
possibility that latent diabetic angiopathy could have an 
effect on FC.
Summary and Conclusions
1. Insulin-dependent diabetics were shown to have a 
reduced FC when compared to normal subjects matched for
age, height, and weight.
2. FC appears to be unrelated to HbAl for 
insulin-dependent diabetics. In addition, the inclusion 
of data for normal subjects creates spurious results by 
apparently capitalizing on inter-group differences.
3. Serum triglyceride levels explain a significant 
proportion of variance in FC for insulin-dependent 
diabetics. However, a large proportion of variance in FC 
remains unexplained and requires further elucidation.
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APPENDICES
appendix A 
Clinical Data Form
Name: _______________ Age: yrs Sex: M F Face: B W 0
Height: 1 ", an Weight: _______ lbs,  kg
Date of Onset: _______  Duration: yrs DKA: Yes No
Ttype of Therapy (check one):
 Conventional (one injection/day)  Moltiple Preprandial injections
 Split Dose (two injections/day)  Portable Infusion Pump
Insulin Dose:  U/24 hr _____ U/kg/24 hr
Type of Insulin [check appropriate type (s) ]:
 R NPH L  U Actrarapid Monotard Ultratard
Other Medication: ________________________ ____________________
Fasted: Yes No Exercise: Yes No Cigarettes: Yes No
Blood Pressure: Systolic: nniHg Diastolic: ____nitiHg
• Cholesterol:  mg% Triglyceride:  mg% Gluoose:  mg%
Oorplicaticns (es^ >lain): ______________________________________
Preocclusion ELT: _____min min x min
Postocclusion ELT: min min x min
AELT%: ____ %
G-Hb%: % % x = %
Appendix B 
Subject Consent Form
I, ________________  , volunteer to participate in the
experiment entitled, "Hie Relationship Between Fibrinolytic Capacity 
and Metabolic Control in Insulin-Dependent Diabetes Mellitus," to be 
conducted at Earl K. Long Memorial Hospital, during the period July 
1, 1982 to August 31, 1982, with Guyton Hornsby as Principal 
investigator. The procedures to be followed and their purposes have 
been explained to me and I understand them. I further understand 
that I can withdraw from the experiment at any time, that the data I 
will provide will be anonymous and ny identity will not be revealed 
without my permission, and that ny performance in this experiment may 
be used for additional approved projects. Finally, I shall be given 
the opportunity to ask questions prior to the start of the experiment 
and after my participation is complete.
Subject's signature
Appendix C
Fibrinolytic Capacity* Glycosylated Hemoglobin, and Serum Glucose, 
Cholesterol, and Triglyceride for Diabetic Subjects
Subject PC
(%)
HhAl
(%)
GLU
(mg%)
CHO
(mg%)
TRI
(mg%)
Subject PC
(%)
HbAl
(mg%)
GLU CHO TRI 
(mg%) (mg%) (mg%)
D1 74.4 6.5 182 200 45 D14 47.8 13.7 317 304 75
D2 57.3 11.5 354 264 51 D15 39.2 11.6 274 213 131
D3 31.1 7.5 134 164 51 D16 28.5 10.1 266 160 37
D4 31.2 10.4 106 170 41 D17 28.0 13.3 283 168 122
D5 41.9 9.8 94 217 94 D18 71.5 9.4 292 212 45
D6 73.3 12.8 244 213 47 D19 53.4 6.8 177 130 49
D7 27.1 10.5 69 197 51 D20 54.3 7.5 394 176 89
D8 26.2 9.7 99 298 110 D21 57.8 10.1 59 * 72
D9 72.1 8.9 148 123 62 D22 73.0 12.5 272 252 *
DIO 22.6 8.6 181 126 29 D23 58.6 12.6 407 247 56
Dll 15.7 13.3 287 262 93 D24 45.1 8.1 178 210 71
D12 69.4 12.8 242 304 75 D25 10.8 11.1 44 278 330
D13 51.2 8.5 180 193 38 D26 49.6 10.9 158 288 *
H 46.6 10.3 209 215 78
± SD 19.3 2.1 102 56 60
n 26 26 26 25 24
* Missing Data
Appendix D
Fibrinolytic Capacity, Glycosylated Hemoglobin, and Serum Glucose, 
Cholesterol, and Triglyceride for Nondiabetic Subjects
Subject PC HhAl GLU CHO TRI Subject PC HhAl GLU CHO TRI
Cl 72.9 7.7 96 171 46 Cll 67.9 6.2 105 183 53
C2 79.8 8.1 93 215 47 Cl 2 44.7 5.6 90 199 36
C3 76.1 6.4 91 186 34 C13 61.7 5.6 107 249 56
C4 41.9 6.0 97 227 82 C14 62.5 7.8 88 173 69
C5 76.9 7.1 105 175 44 C15 64.9 7.1 92 157 41
C6 47.4 6.5 94 217 80 C16 72.3 6.3 78 197 55
C7 54.5 5.5 * 162 43 C17 46.2 5.7 87 180 76
C8 67.3 5.8 103 190 55 C18 70.5 * 94 172 *
C9 55.5 4.7 103 169 132 C19 72.3 7.0 87 171 48
CIO 81.9 6.3 93 155 34 C20 67.4 7.3 96 166 30
M 64.2 6.5 95 186 56
± SD 12.1 .9 7 25 24
n 20 19 19 20 19
* Missing Data
Appendix E 
Clinical Data for Diabetic Subjects
Duration of Insulin Type of Systolic Diastolic
Subject Age Height Weight Sex Race Diabetes Dose Therapy Corplications B.P. B.P.
(yrs) (an) (kg) (yrs) (U/24 hrs) (nrflg) (nntig)
D1 30 167.6 70.8 M W 15 32 Multiple None 116 72
D2 20 157.5 43.1 F W 8 18 Split None 105 60
D3 31 175.2 64.0 M B' 6 41 Punp Neuropathy 110 80
D4 38 167.6 69.4 F W 6 43 Putp None 112 76
D5 29 165.1 52.2 F W 3 32 Multiple Retinopathy 108 78
D6 29 165.1 56.7 F W 9 44 Split Neuropathy 112 72
D7 17 160.0 48.1 F B 7 76 Split None 110 78
D8 20 160.0 48.1 F W 7 40 Conventional None 116 64
D9 18 162.6 56.2 F W 9 41 Split None 116 64
DIO 23 152.4 42.2 F B 12 28 Split None 116 72
Dll 18 157.5 54.4 F B 5 66 Split None 124 84
Clinical Data for Diabetic Subjects
Subject Age
(yrs)
Height
(cm)
Weight
(kg)
Sex Race
Duration of 
Diabetes 
(yrs)
Insulin Type of
Dose Therapy duplications 
(U/24 hrs)
Systolic
B.P.
(imHg)
Diastolic
B.P.
(nrrHg)
D12 24 155.0 59.0 P B 15 60 Conventional None 118 72
D13 28 165.1 63.2 P W 15 42 Punp Retinopathy 112 78
D14 33 155.0 55.5 F B 7 34 Conventional None 114 80
D15 29 160.0 62.3 F B 5 48 Conventional None 122 80
D16 30 177.8 63.5 M W 18 50 Conventional Retinopathy
Neuropathy
, 112 76
D17 22 170.2 48.1 M W 4 70 Conventional None 112 68
D18 31 185.4 72.6 M W 9 34 Conventional None 120 80
D19 22 172.7 77.6 M W 15 76 Split None 122 84
D20 18 165.1 58.1 F B 11 42 Split None 90 70
D21 17 170.2 57.6 F W 11 93 Split None 116 72
D22 39 170.2 88.5 M B 8 74 Conventional None 132 80
Clinical Data for Diabetic Subjects
Subject Age
(yrs)
Height
(an)
Wteight
(kg)
Sex Race
Duration of 
Diabetes 
(yrs)
Insulin Type of systolic 
Dose Therapy Ccnplications B.P. 
(U/24 hrs) (nntfig)
Diastolic
B.P.
(mrnHg)
D23 16 157.5 49.9 F W 12 50 Split None 106 64
D24 18 167.6 72.6 M W 14 90 S£lit None 120 78
D25 25 167.6 45.8 F W 12 10 Multiple Nephropathy, Reti- 78 
ncpathy, Neuropathy
60
D26 34 177.8 77.1 M B 1 15 Conventional None 118 80
M 25.3 165.7 59.9 9.4 48.0 113 74
± SD 6.8 8.0 11.8 4.3 21.9 10.5 7.1
Sex: F - Female, M - Male 
Race: B - Black, W - White
Type of Therapy: Conventional - Clie injection per day, Split - TVro injections per day,
Multiple - Three or more injections per day, Punp - continuous subcutaneous 
injection by portable infusion punp
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Appendix F 
Clinical Data for Nondiabetic Subjects
Subject Age
(yrs)
Height
(cm)
Weight
(kg)
Sex Race
Systolic
B.P.
(mrriHg)
Diastolic
B.P.
(irinHg)
Cl 26 155.0 49.9 F W 112 68
C2 22 167.6 56.7 F W 122 72
C3 36 170.2 70.3 M W 122 72
C4 36 188.0 86.2 M W 110 60
C5 39 161.3 49.9 F w 116 72
C6 32 177.8 86.2 M w 118 82
Cl 26 165.1 59.0 M w 102 64
C8 27 190.5 86.6 F w 108 68
C9 27 170.1 74.8 M w 118 84
CIO 35 162.5 60.8 F w 108 58
Cll 29 175.3 81.6 M w 124 78
C12 32 162.6 51.7 F w 104 68
C13 24 160.0 51.7 F w 100 64
C14 21 160.0 58.1 F w 98 60
C15 21 172.7 77.1 M w 118 76
C16 26 182.9 88.5 M w 128 78
C17 21 162.5 53.5 F w 100 70
Cl 8 29 167.6 61.2 F w 118 78
C19 26 167.6 52.2 F w 110 70
C20 32 172.7 62.1 M w 118 76
M 28.4 169.7 65.9 113 71
± SD 5.4 9.5 14.0 8.8 7.4
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